Abstract:Background Treatment that targets to cancer stem cells plays an important role in controlling and eliminating of tumor initiation, development, progression, and chemotherapy/radiotherapy resistance.In our previous study, we cultured and harvested human laryngeal cancer stem cells (CSCs), applied microRNA biochips to screen differentially expressed miRNAs that were related to radiation tolerance in irradiated human laryngeal CSCs.According to the predicted genes and pathways of differential miRNAs target, hsa-miR-138-2-3p that was down-regulated expression under radiation, was thought to play a key role in enhancing the radio-sensitivity in human laryngeal squamous cancer stem cells.Method To investigate the radiational enhancement of hsa-miR-138-2-3p, we transfected hsa-miR-138-2-3p mimics that were synthesized based on the sequences of hsa-miR-138-2-3p in vitro into human laryngeal CSCs (Hep-2, M2e, and TU212 cell lines) to make hsa-miR-138-2-3p overexpressed, and the tumorous specialities of CSCs, like cell proliferation, invasion, apoptosis, cell cycle arrest, and DNA damage were evaluated by CCK-8 assay, clone formation assay, invasion assay, flow cytometry, and comet assay.Furthermore, we explored the signal transduction pathways that regulated the cancer stem cell initiation, development, invasion, apoptosis and cell cycle arrest, which were controlled by hsa-miR-138-2-3p.Result Overexpressed hsa-miR-138-2-3p played an key role in many anti-cancer biological process in human laryngeal CSCs: (1) decreased laryngeal CSCs proliferation and invasion in response to radiotherapy; (2) increased the proportion of early and late apoptosis in laryngeal CSCs after radiation, raised G1 phase arrest in laryngeal CSCs after radiation, and decreased the proportion of S stage cells of cell cycle that were related to radio-resistance in laryngeal CSCs; (3) downregulated the expression of β-catenin in Wnt signal pathway that was related to the

Peer Review #1 of "radiosensitization Effect of Hsa-Mir-138-2-3p on Human Laryngeal Cancer Stem Cells (V0.2)"